Imricor Expects Initial US Sales to Exceed Prior-Year European Revenue
IMR: $1.31 -1.50% · MC: $4.5B
Imricor Medical Systems expects revenue from its initial NorthStar sales to exceed its European business’s total revenue for 2025, following its US commercial launch. Two children’s hospitals became its first US customers, with revenue from the Dallas installation expected to be recognised in the fourth quarter. Third-quarter revenue rose more than fivefold from a year earlier, while the net loss narrowed and cash stood at US$62 million. The FDA also cleared paediatric label expansions for NorthStar and the Vision-MR Diagnostic Catheter.

Comments